Efficacy of Sub-gingival Air-polishing With Erythritol in the Treatment of Periodontitis

Periodontitis, Adult Clinical Trial

— GBT2017  

Official title:

Efficacy of Sub-gingival Air-polishing With Erythritol in the Treatment of Periodontitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04264624
• Other study ID #: GBT2017
• Status: Completed
• Phase: N/A
• Start date: February 28, 2018
• Est. completion date: December 10, 2019

Study information

• Verified date: February 2020
• Source: Azienda Ospedaliera Spedali Civili di Brescia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The first step in the management of periodontal disease involves the non-surgical removal of the soft and hard bacterial deposits at all supra- and sub-gingival sites, especially into deep pockets, which can be carried on with different instruments. Unfortunately it seems that, after the initial therapy, many patients still present with active pockets (residual pockets) requiring further treatment and posing a risk of disease progression. This might be due to limitations of the instruments applied and patient-related factors. Air-polishing with low-abrasiveness powders seems to be very effective in the removal of supra- and sub-gingival biofilm and could provide additional benefits during the treatment of pockets.

The hypothesis of the present randomized controlled trial was that the adjunctive use of a sub-gingival nozzle for air-polishing with erythritol powder in pockets with probing depth of 5-9mm and with bleeding (experimental sites) can bring clinical and microbiological advantages during the active therapy of periodontal disease, and reduce the number of residual pockets.

To test this hypothesis, the patients, upon initial evaluation, were divided in 2 study groups:

1. The control group, undergoing a standard procedure involving air-polishing supra-gingivally and at healthy sub-gingival sites followed by debridement with an ultrasonic scaler at deep pathological pockets

2. The study group, undergoing the same procedure but with the additional use of a sub-gingival nozzle at deep pathological pockets.

The healing of the experimental sites and the prevalence of residual pockets will be evaluated at 3 months after the initial therapy and compared between the two groups.

Description:

OUTCOME

1. Primary outcome measure: 3-month change in the number of sites with probing depth (PD) 5-9 mm and positive to bleeding upon probing (BoP). Sites characterized by PD 5-9 mm and BoP+ will be therefore identified as "experimental sites".

2. Secondary outcomes: 3-month changes in the following clinical parameters assessed at experimental sites: clinical attachment level (CAL), PD, number of sites harboring supra-gingival plaque.

3. Other evaluations: Pocket microbiological (subgingival plaque) samples at one (interproximal) experimental site for analysis of periodontal pathogens at baseline and 3 months following treatment.

STUDY POPULATION Forty (40) adults, aged 18-75 years, will be entered into study (randomized). It is expected that at least thirty-two (32) subjects will complete the study.

Randomized subjects who deviate from the protocol (major protocol deviation) and, for this reason, are excluded from the analysis, will be replaced to guarantee that the sample required for the analysis (32) is reached.

Inclusion Characteristics

• Signed Informed Consent Form.

• Male and female subjects, aged 18-75 years, inclusive.

• Good general health (free of systemic diseases such as diabetes, HIV infection or genetic disorder, ongoing malignant disease of any type that could influence the outcome of the treatment and might interfere with the evaluation of the study objectives).

• Moderate to severe periodontitis

• At least 8 experimental sites (PD 5-9 mm and BoP+).

• Availability for the 3-month duration of the study for an assigned subject.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 10, 2019
• Est. primary completion date: October 5, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Signed Informed Consent Form.

• Male and female subjects, aged 18-75 years, inclusive.

• Good general health (free of systemic diseases such as diabetes, HIV infection or genetic disorder, ongoing malignant disease of any type that could influence the outcome of the treatment and might interfere with the evaluation of the study objectives).

• Moderate to severe periodontitis

• At least 8 experimental sites (PD 5-9 mm and BoP+).

• Availability for the 3-month duration of the study for an assigned subject.

Exclusion Criteria:

• Presence of orthodontic appliances.

• Chronic obstructive pulmonary disease and asthma.

• Tumors or significant pathology of the soft or hard tissues of the oral cavity.

• Current radiotherapy or chemotherapy.

• Pregnant or lactating women.

• Current or past (within 3 months prior to enrolment) assumption of medications that may influence periodontal conditions and/or interfere with healing following periodontal treatment (i.e., corticosteroids, calcium channel blockers, systemic antibiotics, ...).

• History of allergy to Erythritol.

• Restorations on the teeth to be treated which may interfere with treatment administration and/or scoring procedures, at the discretion of the examiner.

• Non-surgical and/or surgical mechanical/manual periodontal debridement within 3 months prior to enrolment.

• Use of systemically administered antibacterial agents to treat periodontal disease or dental prophylaxis within 3 months prior to enrolment.

Related Conditions & MeSH terms

• Aggressive Periodontitis
• Chronic Periodontitis
• Periodontitis
• Periodontitis, Adult
• Periodontitis, Aggressive

Intervention

Device:
• Perioflow and Erythritol powder and ultrasonic debridement
Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
• Airflow and Erythritol powder and ultrasonic debridement
Airflow combined with Erythritol powder will be used as an adjunct therapy

Locations

Country	Name	City	State
Italy	Magda Mensi	Brescia	Lombardia

Sponsors (2)

Lead Sponsor	Collaborator
Azienda Ospedaliera Spedali Civili di Brescia	Università degli Studi di Ferrara

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary outcome measure:3 month and to the end of study ( 1 years)	Sites characterized by PD 5-9 mm and BoP+ will be therefore identified as "experimental sites".	through study completion, an average of 1 year